KRAS and non-small cell lung carcinoma: The situation was changed in 2021 when FDA approved sotorasib, a first KRAS G12C inhibitor, for the treatment of locally advanced or metastatic KRAS G12C-mutant NSCLC patients who received at least one line of systemic therapy.